Condition: Healthy Volunteers · Chronic Kidney Disease · Sponsor: Ingenia Therapeutics INC
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is: Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)). Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use. Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.
This description comes directly from the study's public registry record.
Jennifer Curry, PharmD · 317-726-9118 · jc@curryclinicalconsulting.com
Jinsam You, PhD · 617-440-2518 · jyou@ingeniatx.com
Always discuss trial participation with your own doctor first.
| Nucleus Network | Herston, Brisbane, Australia | Recruiting |
| University of Sunshine Coast-Morayfield | Morayfield, Queensland, Australia | Recruiting |
| University of the Sunshine Coast Clinical Trials-Southbank | Morayfield, Queensland, Australia | Recruiting |
| Pacific Clinical Research Network | Takapuna, Auckland, New Zealand | Recruiting |
| Momentum Clinical Research | Waikanae Beach, Kapiti Coast, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07231679